Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGER | Q15109 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.41 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | AHCY | P23526 | 1/20 | 0.40 |
| ▸ | HPRT1 | P00492 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4094947 | 0.89 | AGER (0.47) | AGERLMNAMAPTGAAMAPK1 | |
| SCHEMBL7210234 | 0.77 | PDE4A (0.60) | ADORA2AADORA1ADORA2BCYP1A2CYP3A4 | |
| SCHEMBL4002739 | 0.75 | TLR7 (0.52) | ADORA2AADORA1ADORA2BADORA3TMIGD3 | |
| SCHEMBL21775530 | 0.74 | ADORA2A (0.41) | ADORA2AADORA1ADORA2BADORA3 | |
| SCHEMBL2554652 | 0.74 | CCNE1 (0.58) | ADORA2AADORA1CYP2C19ALDH1A1AHCY | |
| SCHEMBL4103638 | 0.73 | TLR7 (0.40) | HPRT1 | |
| SCHEMBL3932343 | 0.72 | TLR7 (0.48) | ADORA2AADORA1ADORA2BADORA3 | |
| SCHEMBL13750576 | 0.71 | TLR7 (0.52) | LMNAMAPTKDM4E | |
| SCHEMBL19539674 | 0.71 | TLR7 (0.57) | ADORA2AADORA1ADORA2BADORA3 | |
| SCHEMBL16131314 | 0.71 | CCNE1 (0.57) | ADORA2AADORA1CYP3A4ALDH1A1AHCY |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110831584-B | Targeted drug rescue with novel compositions, combinations and methods thereof | 埃克塞瓦有限责任公司 | 2023-03-10 | — | — | CN | disclosed |
| US-11478467-B2 | Targeted drug rescue with novel compositions, combinations, and methods thereof | Exciva GmbH (DE) | 2022-10-25 | — | — | US | disclosed |
| US-20200261442-A1 | TARGETED DRUG RESCUE WITH NOVEL COMPOSITIONS, COMBINATIONS, AND METHODS THEREOF | VEPACHEDU SREENIVASARAO (US) | 2020-08-20 | — | — | US | disclosed |
| US-20200069674-A1 | TARGETED DRUG RESCUE WITH NOVEL COMPOSITIONS, COMBINATIONS, AND METHODS THEREOF | Exciva GmbH (DE) | 2020-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11478467-B2 | Targeted drug rescue with novel compositions, combinations, and methods thereof | HTR2A, HTR2C, CYP3A43 | AGER 1245/4885LMNA 1421/4885MAPT 3386/4885 |
| US-20200069674-A1 | TARGETED DRUG RESCUE WITH NOVEL COMPOSITIONS, COMBINATIONS, AND METHODS THEREOF | HTR2A, HTR2C, CYP3A43 | AGER 1245/4885LMNA 1421/4885MAPT 3386/4885 |
| US-20200261442-A1 | TARGETED DRUG RESCUE WITH NOVEL COMPOSITIONS, COMBINATIONS, AND METHODS THEREOF | HTR2C, HTR2A, HTR3A | AGER 904/4885LMNA 2085/4885MAPT 3208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.